ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Roche, PhoenixMD collaborate on diagnostic that may help identify triple-negative breast cancer patients who might benefit from RSK inhibitor PMD-026
January 17, 2019In September, PhoenixMD announced that it raised $2.7 million to advance PMD-026 through investigational new drug (IND)-enabling studies and to develop a companion diagnostic to determine which patients have high levels of activated RSK2. -
Roche, PhoenixMD collaborate on diagnostic that may help identify triple-negative breast cancer patients who might benefit from RSK inhibitor PMD-026
January 17, 2019In September, PhoenixMD announced that it raised $2.7 million to advance PMD-026 through investigational new drug (IND)-enabling studies and to develop a companion diagnostic to determine which patients have high levels of activated RSK2.
Pharma Sources Insight January 2025
